^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    BluePrint

    Company:
    Agendia
    Type:
    CE Marked
    Related tests:
    BluePrint is an 80-Gene Molecular Subtyping Test which allows for the classification of breast cancer into RNA-based functional molecular subtypes which is not possible using current standard pathological tests. BluePrint evaluates the functionality of receptor cell signaling and complements IHC/FISH. It provides information regarding patient chemotherapy or hormonotherapy resistance for more informed treatment decision-making.
    Cancer:
    Breast Cancer
    Gene:
    HER-2 (Human epidermal growth factor receptor 2)
    Method:
    Immunohistochemistry (IHC) / Fluorescence in situ hybridization (FISH)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    08/16/24
    BC
    -
    CE
    Confirmatory trial(s)
    NBRST
    ,
    NCT01479101
    |
    J Clin Oncol